Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel plus prednisone vs mitoxantrone plus prednisone in hormone-refractory metastatic prostate cancer after prior Taxotere
2006-003087-59Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2006
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Sanofi. Primary endpoint: overall survival. Started Aug 2006; status: completed.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2006-003087-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003087-59.